For the year ending 2025-12-31, MRKR had -$2,149,593 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,163,620 |
| Stock-based compensation | 537,540 |
| Prepaid expenses and deposits | 175,033 |
| Other receivables | -977,303 |
| Related party payable | -1,710,500 |
| Accounts payable and accrued expenses | -454,570 |
| Deferred revenue | 974,799 |
| Net cash used in operating activities | -12,014,081 |
| Proceeds from issuance of common stock, net | 9,863,883 |
| Proceeds from exercise of warrants and stock options | 605 |
| Net cash provided by financing activities | 9,864,488 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -2,149,593 |
| Cash, cash equivalents, and restricted cash at beginning of the year | 19,192,440 |
| Cash, cash equivalents, and restricted cash at end of the year | 17,042,847 |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)